DSG3-CAART
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DSG3-CAART, covering 2025-12-17 to 2025-12-17. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) [Phase 1, Phase 2]